VIA Technologies
In 2003, the firm acted for Bayer AG on the £25 million financing aspects of its exclusive marketing agreement with GW Pharmaceuticals plc relating to the marketing of GW's pioneering cannabis-based medicine Sativex®. In the same year, the firm acted for VIA Technologies in a hard-fought competition law battle between leading chip producer Intel and its smaller competitor, VIA Technologies. In this case, the Court of Appeal decided that VIA Technologies can bring Intel to trial, and alleged that Intel's behaviour is anti-competitive, that the way Intel uses its huge patent portfolio seriously harms smaller rivals, and that Intel is driving rivals out of business and harming consumers.